Hannah Slater


Treatment at high-volume facilities linked to improved survival in node-positive prostate cancer

The improved survival was observed in patients treated at high-volume radiation centers with external-beam radiation therapy plus androgen-deprivation therapy.

Jonathan Henderson, MD


“Shooting for the Moon” means reducing metastatic prostate cancer diagnoses

“We have an incredible opportunity to save countless more lives with better screening practices and renewed recommendations, which accurately reflect the realities we as independent physicians see within our patient populations every day,” Jonathan Henderson, MD, writes in this letter to the editor.

Eric A. Singer, MD, MA, FACS


Clinical Pearls and Future of Bladder Cancer Treatment

Eric A. Singer, MD, MA, FACS, looks to the future of bladder cancer treatment and offers advice for community urologists and urologic oncologists treating patients with the disease.

Alan H. Bryce, MD


Urologic implications of Lynch syndrome

Research indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.

Bryn Launer, MD


Considerations for palliative care in urologic oncology

Benefits include improved quality of life and symptom management.

United Urology Group


United Urology Group and its affiliate practices and Prostate Centers USA® are collaborating to revolutionize men's health care with minimally invasive solutions

The inclusion of PAE in the American Urological Association BPH Guidelines offers a non-surgical alternative that can provide long-term relief with minimal downtime and fewer complications, according to the United Urology Group.

Colleen Moretti


Triplet therapy including darolutamide should be standard of care in mCSPC, data indicate

Results of the ARASENS trial (NCT02799602) demonstrated that darolutamide plus ADT and docetaxel prolonged overall survival regardless of disease volume or risk.

Brielle Benyon


Belzutifan demonstrates superior PFS, ORR to everolimus in ccRCC

“Belzutifan demonstrated a significant improvement in PFS with a hazard ratio of .75, and a significant P value. Similar findings were noted at the second interim analysis with a hazard ratio of .74,” says Laurence Albiges, MD, PhD.

Parviz K. Kavoussi, MD


Chronic orchialgia: How to diagnose and treat the challenging condition

In this interview, Parviz K. Kavoussi, MD, discusses his diagnostic work-up for patients who present with chronic testicular pain and describes conservative and surgical management approaches for the condition.

Terri Gatchel-Schmidt


Expert explains why automation is key to prior authorization reform

Automating prior authorization is an investment that every health care organization should consider. As the industry grapples with rapid regulatory shifts and acute staff shortages, a tailored automation strategy is key to enhancing patient care and improving operational efficiency.

Chelsea King Arthur


How data and technology facilitate health equity and boost the overall patient experience

"Digital engagement technology, which can be seamlessly integrated into a health system or hospital's existing processes," writes Chelsea King Arthur.

Brian Hudson


Is a medical scribe right for your practice?

“Regardless of the size of the practice, medical scribes are a valuable resource for health care providers, helping to streamline workflow and coordinate patient care,” writes Brian Hudson.

Glenn T. Werneburg, MD, PhD


Diagnostic stewardship for urinary tract infection: A snapshot of the expert guidance

Urinary tract infections (UTIs) are among the most common human infections. But the urine culture, the cornerstone for laboratory diagnosis of UTI, is imperfect.

Kristi Rosa


Olaparib shows promise in kidney cancer subtype

The PARP inhibitor olaparib demonstrated antitumor activity in patients with BAP1-mutated renal cell carcinoma.

Gina Mauro


Cabozantinib/atezolizumab does not improve PFS or OS in advanced RCC

“The addition of atezolizumab to cabozantinib did not result in improved clinical outcomes in patients with mRCC who progressed on or after prior ICI treatment,” said Toni K. Choueiri, MD.

Scott T. Tagawa, MD, MS, FACP, FASCO


Clinical Insights on Evolving Treatment Landscape in Urothelial Carcinoma

Scott T. Tagawa, MD, MS, FACP, FASCO, offers a comprehensive look at the evolving treatment landscape, with a focus on practical considerations and ongoing research.

Ariana Pelosci


Dr. Gupta highlights the latest developments in muscle-invasive bladder cancer

Shilpa Gupta, MD, shares her expert insight on the evolving treatment paradigm for patients with muscle-invasive bladder cancer, along with obstacles that must be overcome to further advance the field.

Kansas University Department of Urology


How to assemble a Thompson Retractor for midline transabdominal retroperitoneal surgery

The patient presented with a large right renal mass who elected for right radical nephrectomy with possible inferior vena cava.

Amar U. Kishan, MD


Clinical Insights on Optimal Perirectal Spacing

In the third article of this series, Amar U. Kishan, MD, provides clinical insights on the use of perirectal spacers for patients who receive hypofractionated radiation or SBRT.

Heidi Moawad, MD


Tips for successfully mentoring other physicians

Here are some helpful hints for launching your physician mentor-mentee relationship.

Audrey Sternberg


Dr. Lara reviews the evolving systemic therapy paradigm in renal cell carcinoma

“The question of who is a candidate for active surveillance is hard to answer because this is a bedside, gut decision," says Primo Nery Lara, Jr, MD.

Michael S. Cookson, MD, MMHC


The struggle is real: Keeping up with the rapidly evolving clinical evidence in urology

"Keeping up-to-date is challenging, and rapid progress that is now occurring in our field is truly amazing," writes Michael S. Cookson, MD, MMHC, FACS.

Leah Ashton, MD


Tips for optimizing productivity and collaboration for trainees who go unmatched in urology

"Going into the upcoming application cycle, I am now a bit more excited and a little less terrified," writes Leah Ashton, MD.

Michael Brickman, MD


Leveraging technology to empower patients and reduce physician burnout

Implementing the right practice technology can not only mitigate physician burnout, it can also enable patients to take charge of their own care experience.

Johnny Pallares


Expert shares best practices for keeping a medical office clean

Here are 5 best practices for cleaning a medical office.

Thomas E. Hutson, PharmD, DO


PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Tyler Bergeron, BS


Artificial intelligence is the new ghost author in urological research

“Although the future of AI within science is uncertain, disclosure of the use of AI is an excellent first step to balance academic integrity with disruptive innovation,” the authors write.

Brian Mazzarella, MD


Urology Perspective on Radiation Toxicity in Prostate Cancer

Urologists offer their perspectives on toxicity seen in patients with prostate cancer who are undergoing radiation treatment.

Peter Reilly


Workplace violence in health care remains rampant as preventive efforts continue

Even before the pandemic, violence against health care workers was escalating.

© 2023 MJH Life Sciences

All rights reserved.